Free Trial
NYSE:BLCO

Bausch + Lomb (BLCO) Stock Price, News & Analysis

Bausch + Lomb logo
$14.12 -0.38 (-2.60%)
Closing price 03:59 PM Eastern
Extended Trading
$14.10 -0.02 (-0.16%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Bausch + Lomb Stock (NYSE:BLCO)

Key Stats

Today's Range
$13.99
$14.57
50-Day Range
$14.18
$17.90
52-Week Range
$13.16
$21.69
Volume
882,286 shs
Average Volume
608,298 shs
Market Capitalization
$4.98 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.18
Consensus Rating
Hold

Company Overview

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Remove Ads

Bausch + Lomb Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
78th Percentile Overall Score

BLCO MarketRank™: 

Bausch + Lomb scored higher than 78% of companies evaluated by MarketBeat, and ranked 221st out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bausch + Lomb has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 4 buy ratings, 7 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Bausch + Lomb has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Bausch + Lomb's stock forecast and price target.
  • Earnings Growth

    Earnings for Bausch + Lomb are expected to grow by 29.73% in the coming year, from $0.74 to $0.96 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bausch + Lomb is -15.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bausch + Lomb is -15.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Bausch + Lomb has a PEG Ratio of 0.85. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Bausch + Lomb has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Bausch + Lomb's valuation and earnings.
  • Percentage of Shares Shorted

    5.63% of the float of Bausch + Lomb has been sold short.
  • Short Interest Ratio / Days to Cover

    Bausch + Lomb has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bausch + Lomb has recently increased by 9.68%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Bausch + Lomb does not currently pay a dividend.

  • Dividend Growth

    Bausch + Lomb does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.63% of the float of Bausch + Lomb has been sold short.
  • Short Interest Ratio / Days to Cover

    Bausch + Lomb has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bausch + Lomb has recently increased by 9.68%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Bausch + Lomb has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Bausch + Lomb this week, compared to 5 articles on an average week.
  • Search Interest

    3 people have searched for BLCO on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bausch + Lomb insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.15% of the stock of Bausch + Lomb is held by insiders.

  • Percentage Held by Institutions

    Only 11.07% of the stock of Bausch + Lomb is held by institutions.

  • Read more about Bausch + Lomb's insider trading history.
Receive BLCO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch + Lomb and its competitors with MarketBeat's FREE daily newsletter.

BLCO Stock News Headlines

Wells Fargo Downgrades Bausch + Lomb (BLCO)
Elon Set to Shock the World by May 1st ?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.
See More Headlines

BLCO Stock Analysis - Frequently Asked Questions

Bausch + Lomb's stock was trading at $18.06 at the start of the year. Since then, BLCO shares have decreased by 21.8% and is now trading at $14.1230.
View the best growth stocks for 2025 here
.

Bausch + Lomb Co. (NYSE:BLCO) announced its earnings results on Wednesday, February, 19th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.02. Bausch + Lomb's revenue for the quarter was up 9.1% on a year-over-year basis.

Bausch + Lomb (BLCO) raised $788 million in an initial public offering on Friday, May 6th 2022. The company issued 35,000,000 shares at a price of $21.00-$24.00 per share.

Shares of BLCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bausch + Lomb investors own include PayPal (PYPL), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Walt Disney (DIS), Intel (INTC) and Devon Energy (DVN).

Company Calendar

Last Earnings
2/19/2025
Today
4/01/2025
Next Earnings (Estimated)
4/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Ophthalmic goods
Sub-Industry
Medical Equipment
Current Symbol
NYSE:BLCO
Fax
N/A
Employees
12,500
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.18
High Stock Price Target
$25.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+32.3%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
12 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
19.59
P/E Growth
0.85
Net Income
$-317,000,000.00
Pretax Margin
-4.88%

Debt

Sales & Book Value

Annual Sales
$4.79 billion
Cash Flow
$1.72 per share
Price / Cash Flow
8.41
Book Value
$18.57 per share
Price / Book
0.78

Miscellaneous

Free Float
351,940,000
Market Cap
$5.11 billion
Optionable
Optionable
Beta
0.49
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NYSE:BLCO) was last updated on 4/1/2025 by MarketBeat.com Staff
From Our Partners